《2022ESCMID/EUCIC临床实践指南:多重耐药革兰阴性菌定植患者围手术期的抗菌药物预防》解读  

Interpretation of ESCMID/EUCIC Clinical Practice Guidelines on Perioperative Antibiotic Prophylaxis in Patients Colonized by Multidrug-resistant Gram-negative Bacteria

作　　者：阳柳 边原[1] 杜姗[1] 周杨林[1] 王玥媛 YANG Liu;BIAN Yuan;DU Shan;ZHOU Yanglin;WANG Yueyuan(Department of Pharmacy,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Affiliated Hospital of University of Electronic Science and Technology of China,Chengdu 610072,China)

机构地区：[1]四川省医学科学院·四川省人民医院(电子科技大学附属医院)药学部,成都610072

出　　处：《医药导报》2024年第4期484-488,共5页Herald of Medicine

基　　金：国家重点研发计划资助项目(2020YFC2005506);四川省科技厅自然科学基金(2022NSFSC0818)。

摘　　要：2022年12月,ESCMID/EUCIC联合发布了《多重耐药革兰阴性菌定植患者围手术期抗菌药物预防的临床实践指南》。指南依据已发表的多重耐药革兰阴性菌(MDR-GNB)定植患者围手术期抗菌药物预防的研究进行系统评价后制定。指南就MDR-GNB定植筛查的必要性与筛查时机、围手术期抗菌药物的选择与用药时间等问题进行阐述,并提供了基于现有研究的循证建议。本文结合国内外最新研究进展对该指南进行解读,以期减少MDR-GNB定植患者手术部位感染的发生,使患者获益。In December 2022,ESCMID/EUCIC jointly issued the Clinical Practice Guidelines for perioperative antimicrobial prophylaxis in patients colonized with multidrug-resistant Gram-negative bacteria(MDR-GNB).The guideline was based on systematically evaluating of published studies on perioperative antimicrobial prophylaxis in patients colonized with MDR-GNB.The guideline elaborated on the necessity and timing of screening for MDR-GNB colonization,perioperative antimicrobial prophylaxis selection,and the timing of dosing,and it provided evidence-based recommendations based on existing studies.This paper interpreted the guidelines based on the latest research progress at home and abroad,aiming to reduce the occurrence of surgical site infections in patients colonized with MDR-GNB and benefit patients.

关 键 词：多重耐药革兰阴性菌 围手术期抗菌药物预防 手术部位感染 

分 类 号：R978[医药卫生—药品]